These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 17010757)
21. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Rothschild S; Bucher SE; Bernier J; Aebersold DM; Zouhair A; Ries G; Lombrieser N; Lippuner T; Lütolf UM; Glanzmann C; Ciernik IF Int J Radiat Oncol Biol Phys; 2011 May; 80(1):126-32. PubMed ID: 20646869 [TBL] [Abstract][Full Text] [Related]
22. Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. Kim JH; Kim HS; Choi JS; Lee KM; Shin YC; Ahn BM; Choi DR; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Zang DY Lung Cancer; 2009 Apr; 64(1):121-3. PubMed ID: 19022521 [TBL] [Abstract][Full Text] [Related]
23. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K; Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997 [TBL] [Abstract][Full Text] [Related]
24. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Argiris A; Mittal N Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090 [TBL] [Abstract][Full Text] [Related]
25. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612 [TBL] [Abstract][Full Text] [Related]
26. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures. Treudler R; Zouboulis CC Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753 [No Abstract] [Full Text] [Related]
27. Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Matsuo K; Kiura K; Tabata M; Uchida A; Hotta K; Niiya D; Kubonishi S; Ogino A; Fujiwara Y; Nakajima H; Shinagawa K; Ishimaru F; Ueoka H; Tanimoto M Am J Hematol; 2006 May; 81(5):349-54. PubMed ID: 16628731 [TBL] [Abstract][Full Text] [Related]
28. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486 [TBL] [Abstract][Full Text] [Related]
29. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604 [TBL] [Abstract][Full Text] [Related]
30. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. Campbell TM; Brown CW J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770 [TBL] [Abstract][Full Text] [Related]
31. Gefitinib (IRESSA, ZD 1839) as a salvage treatment for patients with advanced non-small cell lung cancer. Jubelirer SJ; Yadwadkar KS; Kosowicz AB W V Med J; 2006; 102(6):14-7. PubMed ID: 17334161 [TBL] [Abstract][Full Text] [Related]
32. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743 [TBL] [Abstract][Full Text] [Related]
33. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Siegel-Lakhai WS; Beijnen JH; Schellens JH Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282 [TBL] [Abstract][Full Text] [Related]
34. Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program. Gridelli C; Rossi A; Maione P; Guerriero C; Airoma G; Colantuoni G; Barzelloni ML Anticancer Res; 2004; 24(3b):1873-7. PubMed ID: 15274368 [TBL] [Abstract][Full Text] [Related]
36. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815 [No Abstract] [Full Text] [Related]
38. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? Stinchcombe TE; Socinski MA Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157 [TBL] [Abstract][Full Text] [Related]
39. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406 [TBL] [Abstract][Full Text] [Related]